Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas

Simone Ferrero, Umberto Leone Roberti Maggiore, Nicoletta Aiello, Fabio Barra, Antonino Ditto, Giorgio Bogani, Francesco Raspagliesi, Domenica Lorusso

Research output: Contribution to journalArticle

Abstract

Introduction: Uterine leiomyosarcomas (ULMS) represent 1.3% of all uterine malignant tumors. Surgery is the curative treatment for patients with early stage disease. In case of advanced, persistent or recurrent tumor, chemotherapy represents the standard of care, but these patients have a poor prognosis. As the results with available therapies are far from being satisfactory, research is focusing on identification of new compounds. In 2012 the Food and Drug Administration (FDA) licensed pazopanib for the treatment of advanced soft-tissue sarcomas failing previous chemotherapy. Areas covered: The aim of this article is to review the literature on the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of the tyrosine kinase inhibitor (TKI), pazopanib in the treatment of ULMS. Expert opinion: The discovery of some relevant signalling pathways in LMS cells led to the development of new targeted drugs with promising results in the management of these tumors. Pazopanib is a multi-target second-generation TKI with activity against growth factors involved in angiogenesis. It has shown promising results both in terms of efficacy and safety, as shown in the EORTC 62043 Study and the PALETTE trial. Further studies are awaited to evaluate its efficacy in uterine leiomyosarcomas.

Original languageEnglish
Pages (from-to)881-889
Number of pages9
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume13
Issue number8
DOIs
Publication statusPublished - Aug 3 2017

    Fingerprint

Keywords

  • angiogenesis
  • pazopanib
  • soft tissue sarcomas
  • targeted drug
  • Uterine leiomyosarcomas

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this